Aquestive Therapeutics (NASDAQ:AQST) Given New $8.00 Price Target at Piper Sandler

Piper Sandler has raised its price target for Aquestive Therapeutics (NASDAQ:AQST) from $5.00 to $8.00, maintaining an "overweight" rating. This suggests a potential upside of 30.51% from the current price. Other analysts have also upgraded their ratings, with Zacks moving from "hold" to "strong-buy". The stock opened at $6.13, with a market cap of $611.28 million. Recent insider sales and institutional investments indicate active trading around the stock, which has an average rating of "Buy" and a consensus price target of $10.00.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) had its price objective increased by research analysts at Piper Sandler from $5.00 to $8.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has an "overweight" rating on the stock. Piper Sandler's price objective would suggest a potential upside of 30.51% from the company's current price.

Other analysts have also recently issued research reports about the stock. Zacks Research raised shares of Aquestive Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Friday, October 17th. Citigroup reissued an "outperform" rating on shares of Aquestive Therapeutics in a report on Thursday, October 9th. Oppenheimer lifted their price target on Aquestive Therapeutics from $7.00 to $8.00 and gave the stock an "outperform" rating in a research note on Monday, September 8th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Aquestive Therapeutics in a report on Wednesday, October 8th. Finally, JMP Securities lifted their price target on shares of Aquestive Therapeutics from $9.00 to $12.00 and gave the company a "market outperform" rating in a research report on Thursday, October 9th. Two analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Aquestive Therapeutics has an average rating of "Buy" and a consensus price target of $10.00.

Get Aquestive Therapeutics alerts:

Read Our Latest Stock Analysis on AQST

Aquestive Therapeutics Trading Up 2.2%

Shares of AQST opened at $6.13 on Friday. The firm has a market cap of $611.28 million, a P/E ratio of -8.63 and a beta of 1.79. Aquestive Therapeutics has a 12 month low of $2.12 and a 12 month high of $7.55. The stock's 50 day moving average is $5.84 and its two-hundred day moving average is $4.24.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last announced its earnings results on Wednesday, November 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.01). The firm had revenue of $12.81 million during the quarter, compared to analysts' expectations of $12.94 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. Equities research analysts forecast that Aquestive Therapeutics will post -0.46 EPS for the current year.

Insider Buying and Selling

In related news, insider Carl N. Kraus sold 20,272 shares of the stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $7.00, for a total value of $141,904.00. Following the transaction, the insider owned 282,475 shares of the company's stock, valued at $1,977,325. This represents a 6.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Peter E. Boyd sold 15,000 shares of the firm's stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $5.30, for a total value of $79,500.00. Following the sale, the insider directly owned 288,323 shares in the company, valued at $1,528,111.90. This trade represents a 4.95% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 276,770 shares of company stock worth $1,692,203. 8.35% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Aquestive Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of AQST. Geode Capital Management LLC raised its holdings in shares of Aquestive Therapeutics by 16.2% in the second quarter. Geode Capital Management LLC now owns 1,977,001 shares of the company's stock valued at $6,545,000 after buying an additional 276,295 shares during the last quarter. Pale Fire Capital SE lifted its stake in shares of Aquestive Therapeutics by 25.5% in the second quarter. Pale Fire Capital SE now owns 1,676,451 shares of the company's stock valued at $5,549,000 after purchasing an additional 340,767 shares during the period. Commonwealth Equity Services LLC acquired a new position in Aquestive Therapeutics during the third quarter valued at approximately $5,918,000. Sio Capital Management LLC grew its stake in Aquestive Therapeutics by 141.9% during the second quarter. Sio Capital Management LLC now owns 947,489 shares of the company's stock worth $3,136,000 after buying an additional 555,860 shares during the period. Finally, Federated Hermes Inc. acquired a new stake in Aquestive Therapeutics during the 3rd quarter valued at $4,381,000. 32.45% of the stock is owned by hedge funds and other institutional investors.

About Aquestive Therapeutics

(Get Free Report)

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.

Should You Invest $1,000 in Aquestive Therapeutics Right Now?

Before you consider Aquestive Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aquestive Therapeutics wasn't on the list.

While Aquestive Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here